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Objective: The present paper investigated possible correlations between the clinical presentation of hepa-
titis B and the TNF-a 308G/A, IFN-c +874A/T, TGF-beta1 509C/T, and IL-10 1081A/G polymorphisms
and associated serum levels of these cytokines.
Methods: Fifty-three hepatitis patientswere selected and divided into two groups: A – inactive (n = 30) and
B – chronic hepatitis/cirrhosis (n = 23). The control group consisted of 100 subjects who were positive for
anti-HBc and anti-HBs. The serum concentrations of the cytokines were determined by immunoenzymatic
assays. The polymorphisms of the cytokines genes were assessed by PCR and PCR-SSP.
Results: Themean serum levels of IFN-c of the control groupwere signiﬁcantly higher than those of groups
A and B, whereas themean levels TGF-beta1were signiﬁcantly higher in groups A and B in comparisonwith
the control. In the case of IL-10, themean serum level recorded in the control groupwas signiﬁcantly higher
than that of group B. The TNF-a308AG genotype was considerablymore frequent in group B (43.3%) than
the control (14.4%).
Conclusion: Higher serum levels of IFN-c and TGF-beta1 were associated with chronic hepatitis B, and
lower serum levels of IL-10 were found in patients with the active disease. Furthermore the presence of
allele A of the TNF-a 308 polymorphism suggest a risk of the progressive disease.
 2013 Elsevier Ltd. Open access under the Elsevier OA license.1. Introduction
Worldwide, it is estimated that over 2 billion people have had
contact with the hepatitis B virus (HBV), and that 350–400 million
are chronically infected, of which approximate 15–40% will evolve
to decompensation. An estimated 500,000–1 million deaths are
attributed to this infection each year, resulting from complications
caused by cirrhosis or hepatocellular carcinomas (HCC) [1].
Once infected with HBV, the subject may have an acute self-
limited infection or evolve to chronicity. The chronic form of hepati-
tis B is characterized by several phases, including immunotolerance,
chronic hepatitis with positive or negative HBeAg, as well as the
chronic disease carrier [2–4]. This complex clinical framework is
the result of the interaction of factors inherent to the host and the
virus, as well as environmental conditions, but is related primarily
to the age and immunological status of the infected person [3,5–7].
The understanding of the complex virus–host interaction,
which results in a variety of clinical manifestations, necessarily
requires a good working knowledge of the immunopathogenesis).
sevier OA license.of the disease and the importance of the immunological proﬁle
of the host and its cytokine secretion pattern [8,9].
The proinﬂammatory cytokines TNF-a and IFN-c are critical to
viral clearance in the acute phase [9–11], while in the chronic hep-
atitis phase, the production and function of these cytokines are al-
tered by the immune deﬁciency of the host and the viral escape
mechanism [12–14]. Chronic HBV patients are assumed to have a
predominance of the Th2 response over that of Th1, resulting in
an increase in the production of anti-inﬂammatory cytokines, such
as IL-10 [13,15]. The persistent activation of the star cells in the li-
ver stimulates the continuous synthesis of TGF-beta1 by these
cells, which has a restorative function, and the synthesis of colla-
gen, which has an antagonistic effect to the action of the inﬂamma-
tory cytokines [16–19].
A number of studies have attempted to associate speciﬁc muta-
tions in the cytokine genes with a given pattern of secretion
[20,21], as well as their inﬂuence on the evolution of chronic hep-
atitis B [19,22–25]. The present study describes the serum levels
associated with the polymorphisms in the TNF-a 308G/A, IFN-c
+874T/A, TGF-b1 509C/T and IL-10 1082A/G genes in patients
with chronic hepatitis B, in order to identify speciﬁc immunoge-
netic markers associated with chronic HBV infection.
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2.1. Populations examined
Following the approval of the project by the research ethics
committee, 53 chronic (HBC) hepatitis B patients (36 males and
17 females) were selected from those being treated at a renowned
hepatology clinic in the northern Brazilian city of Belém (Pará
state) between January 2007 and December 2008. The patients
were divided into two groups: (A) inactive carriers, deﬁned by
the presence of HBeAg negative, viral load lower than 2000 UI/
mL, and normal levels of alanine aminotransferase; and (B) those
with chronic hepatitis with cirrhosis or not (HBeAg negative or po-
sitive, high viral load, liver biopsy with inﬂammatory activity or
ﬁbrosis higher or equal to #2 on the scale METAVIR, and high levels
of alanine aminotransferase). The control group comprised 97
healthy people (39 males and 58 females) with natural immunity
to HBV, positive anti-HBc IgG and anti-HBs, and negative anti-
HCV and anti-HIV. The members of both groups were resident in
the northern Brazilian city of Belém (capital of the State of Pará)
and were of similar ethnic origin. All patients were clinically eval-
uated and submitted to biochemical tests, ultrasound, endoscopy,
and, if possible, liver biopsy. Patients co-infected with HCV, HDV,
and HIV were excluded from this analysis.
2.2. Ethical considerations
The individuals were briefed about the project and those who
accepted were given an inform consent to sign. The present work
was submitted and approved by the Ethics Committee of the Santa
Casa de Misericórdia do Pará Foundation and followed the Brazil-
ian Guidelines and Regulatory Standards for Research Involving
Human Subjects (Resolutions 196/1996 and 347/2005 of the Bra-
zilian National Health Council).
2.3. Serology and viral load
Serological analyses (HBsAg, anti-HBc IgG and IgM, HBeAg, anti-
HBe, and anti-HBs) were conducted using an enzyme immunoassay
kit (Organon Teknika, Netherlands; Abbott, USA; Ortho Clinical
Diagnostics, Germany) according to the manufacturers’ instruc-
tions. Viremias were quantiﬁed by the hybridization method using
the AMPLICOR (Roche, USA) commercial kit, which has detection
limit of 60 UI/mL.
2.4. Cytokine serum levels
Plasma levels of TNF-a, INF-c, TGF-b1, and IL-10 were quanti-
ﬁed at the ICB/UFPA Virology Laboratory of Virology using anTable 1
List of the primer sequences and methods used for investigating the TNF, IFN, TGF-b1 and
Polymorphism Method Primer
TNF-a 308G > A RFLP (NcoI) TNF-a
TNF-a
IFN-c +874T > A SSP-PCR IFN-c P
IFN-c T
IFN-c A
TGF-b1 509C > T RFLP (DdeI) TGF-b1
TGF-b1
IL-10 1082A > G RFLP (MnlI) IL-10 F
IL-10 Renzyme immunoassay (Human ELISA Ready-SET-Go, EBioscience,
Inc. California, San Diego, USA). This test was based on the use of
a speciﬁc monoclonal antibody for each of the markers mentioned
above, according to their speciﬁc protocols.2.5. Evaluation of the polymorphisms of the cytokine genes
The polymorphisms of the TNF-a, INF-c, TGF-b1, and IL-10
genes were evaluated by PCR gene ampliﬁcation followed by the
analysis of restriction fragment length polymorphisms (RFLPs) or
the ampliﬁcation of speciﬁc alleles (Table 1). The DNA was ex-
tracted from peripheral blood leukocytes, using the Puregene kit
from Gentra Systems, Inc., USA. The ampliﬁed products were elec-
trophoresed (100 V/45 min) in 3% agarose gel with TAE 1 buffer
(TAE 40 stock – TrisBase 1.6 M, 0.8 M Na acetate and EDTA-Na2
40 mM/1000 mL deionized water), containing 5 lL of ethidium
bromide (10 mg/mL), and visualized by transillumination with a
source of ultraviolet light.2.6. Statistical analysis
The parametric data were analyzed using a one or two criteria
Analysis of Variance (ANOVA) and Student’s t. Nonparametric data
were analyzed using the Chi-square (v2) test. Association between
variables was evaluated with use of Spearman’s correlation coefﬁ-
cient. A multivariate Hotelling approach was used in the ANOVAs.
A signiﬁcance level of p = 0.05 (5%) was used in all analyses.3. Results
The distribution of genotype and allele frequencies showed no
statistically signiﬁcant differences when the groups were com-
pared, but the distribution of cytokine alleles and genotypes indi-
cates an association between chronic infection with HBV and the
mutant allele of the TNF-a gene (Table 2).
The mean serum level of TNF-a in patients with chronic hepati-
tis B was 20.04 ± 9.44 pg/mL, while that of the control group was
21.44 ± 15.79 pg/mL (p = 0.574). Similar mean values (p > 0.05)
were also recorded in groups A (20.55 ± 9.99 pg/mL) and B
(19.34 ± 8.81 pg/mL) – see Fig. 1.
The mean serum level of IFN-c in the patients with chronic hep-
atitis B was signiﬁcantly lower (p < 0.0001) than that of the control
group, with mean values of 94.69 ± 33.14 pg/mL and 136.78 ±
84.37 pg/mL, respectively. The mean level recorded in the control
group is also signiﬁcantly higher (p < 0.01) than the mean recorded
in either group A (87.44 ± 25.11 pg/mL) or B (104.57 ± 40.22 pg/mL)
– see Fig. 1.IL-10 gene polymorphisms.
Alleles
FW 50-AGG CAA TAG GTT TTG AGG GCC AT-30 G: 87 pb
R 50-TCC TCC CTG CTC CGA TTC ATT CG-30 20 pb
A: 107 pb
C 50-TCA ACA AAG CTG ATA CTC CA-30 T: 262 pb
50-TTC TTA CAA CAC AAA ATC AAA TCT-30 A: 262 pb
50-TTC TTA CAA CAC AAA ATC AAA TCA-3
FW 50-GGA GAG CAA TTC TTA TAG GTG -30 C: 74 pb
R 50-TAG GAG AAG GAG GGT CTG TC-30 46 pb
T: 120 pb
W 50- TCT GAA GAA GTC CTG ATG TC-30 A: 125 pb
50- CTC TTA CCT ATC CCT ACT TCC-30 65 pb
G: 93 pb
65 pb
32 pb
Table 2
Distribution of cytokine alleles and genotypes in hepatitis B patients and controls.
Genotype Control group N (%) Chronic hepatitis B N (%) Group A N (%) Group B N (%) Odds ratio p
TNF-alpha 308 0.019i
GG 82 (84.5) 41 (77.3) 23 (76.6) 12 (51.2)
GA 14 (14.4) 10 (18.9) 06 (20.0) 10 (43.3)
AA 01 (1.1) 02 (3.8) 01 (3.4) 01 (4.5) 0.001j
G 178 (91.7) 92 (86.8) 52 (86.7) 34 (73.9) 2.587a
A 16 (8.3) 14 (13.2) 08 (13.3) 12 (26.1) 2.294b
INF-gamma +874 0.364k
TT 09 (9.4) 07 (13.2) 04 (13.3) 03 (13.0)
TA 37 (28.1) 19 (35.8) 14 (46.7) 05 (21.8)
AA 51 (52.5) 27 (51.0) 12 (40.0) 15 (65.2)
T 55 (28.4) 33 (31.1) 22 (36.7) 11 (23.9) 0.875c 0.372l
A 139 (71.6) 73 (68.9) 38 (63.3) 35 (76.1) 0.533d
TGF-beta1 309 0.569m
CC 24 (24.7) 17 (32.0) 09 (30.0) 08 (34.7)
CT 39 (40.2) 19 (36.0) 09 (30.0) 10 (43.4)
TT 34 (35.1) 17 (32.0) 12 (40.0) 05 (21.9)
C 87 (44.8) 53 (50.0) 27 (45.0) 26 (56.2) 0.813e 0.346n
T 107 (55.2) 53 (50.0) 33 (55.0) 20 (43.8) 0.629f
IL-10 1082 0.866o
AA 47 (48.4) 27 (50.9) 17 (56.7) 10 (43.5)
AG 41 (42.3) 20 (37.7) 10 (33.3) 10 (43.5)
GG 09 (9.3) 06 (11.4) 03 (10.0) 03 (13.0)
A 135 (69.6) 74 (69.8) 44 (73.3) 30 (65.2) 0.982g 0.665p
G 59 (31.4) 32 (30.2) 16 (26.7) 16 (34.8) 1.466h
N = chromosome number; group A = inactive carrier; group B = chronic hepatitis with or without cirrhosis.
a Control vs. chronic hepatitis B (p = 0.011, IC 95% = 1.277–5.241).
b Group A vs. group B (p = 0.157, IC 95% = 0.849–6.196).
c Control vs. chronic hepatitis B (p = 0.709, IC 95% = 0.522–1.466).
d Group A vs. group B (p = 0.109, IC 95% = 0.265–1.071).
e Control vs. chronic hepatitis B (p = 0.462, IC 95% = 0.506–1.306).
f Group A vs. group B (p = 0.327, IC 95% = 0.290–1.364).
g Control vs. chronic hepatitis B (p = 0.982, IC 95% = 0.586–1.644).
h Group A vs. group B (p = 0.491, IC 95% = 0.637–3.377).
i v2 = 11.703 group B vs. control.
j v2 = 11.332 group B vs. control.
k v2 = 4.322.
l v2 = 1.975.
m v2 = 2.929.
n v2 = 2.121.
o v2 = 1.268.
p v2 = 0.813.
942 S.R.S. Conde et al. / Cytokine 61 (2013) 940–944Very signiﬁcantlyhigher serum levels of TGF-b1were recorded in
the patients (1163.00 ± 1084.11 pg/mL) in comparison with the
control group, 422.39 ± 210.54 pg/mL (p < 0.0001). Similar differ-
ences were observed between the control group and the values re-
corded for groups A (1201.77 ± 1207.58 pg/mL) and B (1108.09 ±
777.44 pg/mL). On the other hand, serum levels of IL-10were signif-
icantly higher in the control group (39.83 ± 15.82 pg/mL) in compar-
isonwith the patients in general (32.97 ± 10.77 pg/mL), and those of
groups A (30.35 ± 8.21 pg/mL) and B (34.49 ± 11.07 pg/mL).
Correlation analysis between serum levels of cytokines with the
viral load showed no association. Similar results were obtained
from the comparison between the SNPs and viremia levels (data
not shown).
4. Discussion
The present study recorded a signiﬁcantly higher prevalence of
chronic hepatitis B in males and also older individuals in compar-
ison with those with spontaneous resolution. This is consistent
with the ﬁndings of previous studies, which have shown a three-
to sixfold propensity in males for the development of the chronic
condition, which may be explained by the theoretically protective
effects of estradiol, which induces the production of IFN-c. This
hormone supports the seroconversion of antibodies to anti-HBs
and anti-HBe in acute cases, as well as providing an antioxidant ef-fect in the chronic phase, which may lead to a more benign clinical
progression in premenopausal women [26].
The distribution of TNF-a genotypes in the study groups was
similar to that recorded in previous studies in Asia and Brazil
[22,27]. The present study identiﬁed a 2.6-fold higher risk of devel-
oping the chronic disease in individuals with the A allele. Jeng et al.
[28] also recorded a fourfold risk of chronic HBV in carriers with
HCC.
The analysis of the 308G/A intergroup of the TNF-a polymor-
phism indicated a signiﬁcant increase in the GA genotype in pa-
tients with the active disease (group B) in comparison with the
control group. This mutation has been related to more aggressive
development of the disease [29].
The mutant IFN-c +874T/A allele was relatively frequent in all
groups, indicating a lack of any systematic relationship with the
risk of chronic HBV infection. These ﬁndings contrast with those
from other studies [19,30,31] in which the +874AA genotype was
associated with an increased risk of chronic HBV and the A allele
with increased susceptibility to infection. However, conﬂicting re-
sults have been obtained from other studies [22,27], and the exact
effect of this mutation remains unclear.
The +874T > A mutation induces a reduction in the secretion of
IFN-c [32], which is fundamental to the innate and adaptive im-
mune responses of the organism against HBV. Decreased levels of
IFN-c are found in chronic HBV carriers in relation to acute
Fig. 1. Serum levels of TNF-a, INF-c, TGF-b1 and IL-10 in patients with chronic hepatitis B (all patients), inactive carriers (group A), chronic patients (group B), and the control
group. ⁄Probabilities for Student’s t.
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was conﬁrmed by the signiﬁcantly lower serum levels of IFN-c re-
corded in inactive carriers (infected or replicants) in comparison
with the control group.
In the case of the TGF-b1 509C/T polymorphism, in which the
mutation of C to T increases the synthesis of the cytokine, a pre-
dominance of the CT genotype was recorded in both patients and
controls, and no statistical difference was found in the frequency
of this genotype in groups A and B. In their study of patients with
chronic hepatitis B, Migita et al. [22] recorded a frequency of 52.1%
for the CT genotype in the infected group, a value similar to that
recorded in the present study, although in the earlier study, the
principal objective was the evaluation of the risk of the develop-
ment of neoplasia in patients with the mutant T allele, which
was recorded in 85.4% of the HCC cases, and in 68.1% of patients
without HCC.
In the case of another anti-inﬂammatory cytokine, IL-10, the
present study recorded similar frequencies for the IL-10 1082A/
G polymorphism in both patient and control groups, with a
predominance of the AA genotype. An Asian study [30] reported
higher frequencies of the AG genotype in both controls and chronic
patients, but a higher risk of chronic HBV and progression to
cirrhosis in patients with the AA genotype.
Unexpectedly, serum levels of IL-10 were signiﬁcantly higher in
the patients – especially those with the more active form of the
disease – in comparison with the control group. The IL-10 cytokine
is known to be produced by LTh2, which inhibits the action ofIFN-c and controls the suppression of ﬁbrogenesis by stellate cells
mediated by the action of TGF-b1 [33]. In chronic HBV carriers,
there is a predominance of the Th2 response, which hinders Th1-
dependent viral clearance. There is believed to be a concomitant
increase in the action of Treg cells (CD25+), which would increase
the production of IL-10 and suppress the Th1 response stimulated
by HBcAg [15].
The lower serum levels of this cytokine observed in HBV pa-
tients is similar to the pattern recorded in chronic HCV infection,
in which plasma concentrations of IL-10 were signiﬁcantly lower
in infected patients than in uninfected individuals [34,35]. In the
present study, a possible explanation for the elevated levels of IL-
10 found in the control group is the fact that the levels were mea-
sured only in the serum and not the tissue, with no other assess-
ment of the variants of this locus, such as the inﬂuence of
different genotypes on the pattern of cytokine secretion. Sample
size may have been an additional problem.
The balance between the responses of the Th1 and Th2 cells is
known to be essential to the adequate functioning of the system
and viral shedding, which does not occur in patients with chronic
HBV [9,13]. The data available at the present time indicate the
importance of the interaction of three factors in the epidemiology
of hepatitis B – the characteristics of the virus, the host, and the
environment. Given this, an integrated approach will be essential
to a better understanding of the phenomenon.
Advances in all ﬁeld of research, including immunology and
human genetics, will undoubtedly contribute to the eventual
944 S.R.S. Conde et al. / Cytokine 61 (2013) 940–944elucidation of this phenomenon, but it is important to maintain a
holistic view of the human being as an organism, and the social
and environmental contexts of this organism. Future studies with
larger samples and a more ample approach to the problem will
be needed to ratify the results of the present study, and contribute
to the resolution of the many as yet unanswered questions remain-
ing with regard to the immunopathogenesis of chronic HBV
infection.
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